Wedbush Increases Aquestive Therapeutics (AQST) Price Target to $30.00

Aquestive Therapeutics (NASDAQ:AQST) had its price objective raised by Wedbush from $29.00 to $30.00 in a research report sent to investors on Thursday. They currently have an outperform rating on the stock.

A number of other research analysts have also recently commented on AQST. BMO Capital Markets started coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating on the stock. JMP Securities started coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating and a $29.00 price target on the stock. Royal Bank of Canada began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating and a $23.00 price target on the stock. Finally, Zacks Investment Research cut Aquestive Therapeutics from a hold rating to a sell rating in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $27.67.

AQST stock traded down $0.42 during mid-day trading on Thursday, reaching $8.33. The company’s stock had a trading volume of 370 shares, compared to its average volume of 135,038. The company has a current ratio of 3.63, a quick ratio of 3.42 and a debt-to-equity ratio of 1.88. Aquestive Therapeutics has a 12 month low of $7.47 and a 12 month high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Tuesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.15). The business had revenue of $13.27 million during the quarter, compared to analyst estimates of $14.75 million. On average, analysts forecast that Aquestive Therapeutics will post -1 earnings per share for the current year.

In other Aquestive Therapeutics news, CEO Keith J. Kendall bought 7,950 shares of the firm’s stock in a transaction on Friday, November 23rd. The shares were acquired at an average cost of $10.10 per share, for a total transaction of $80,295.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO John T. Maxwell bought 10,000 shares of the firm’s stock in a transaction on Wednesday, November 21st. The stock was acquired at an average price of $9.80 per share, for a total transaction of $98,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 20,650 shares of company stock worth $205,581 in the last three months.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Keybank National Association OH bought a new position in Aquestive Therapeutics in the 3rd quarter worth about $239,000. Point72 Asset Management L.P. bought a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $350,000. Citadel Advisors LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $451,000. Engineers Gate Manager LP bought a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $464,000. Finally, Brant Point Investment Management LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $622,000. Institutional investors and hedge funds own 64.49% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Featured Article: What is a Fiduciary?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply